Skip to content

Rhythm Pharmaceuticals

US · RYTM #1874 by market cap Listed 2017
112.36 -4.44 -3.80%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 116.74 -0.05%
After-hours 113.50 +1.01%
119.0484.35112.362026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RYTM?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +7.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 17.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 89.7% Better than 96%
Operating margin -101.2% Better than 7%
Net margin -106.4% Better than 7%
Return on equity -251.1% Better than 2%
Return on invested capital -233.8% Better than 1%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 2.1% Better than 79%
6-month return 27.9% Better than 88%
12-month return (ex latest month) -12.3% Better than 21%
Distance below 52-week high 8.1% Better than 88%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.4x Better than 83%
Debt to assets 0.8% Better than 93%
Interest coverage -8.5x Better than 14%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 93.3% Better than 76%
Upside to average target 33.2% Better than 52%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.31%
1M +24.57%
3M +3.16%
6M +23.96%
YTD +4.97%
1Y +11.62%
3Y +237.01%
5Y +990.87%

Key statistics

Price & volume

Prev close
116.80
Open
115.46
Day range
112.00 - 117.01
Avg price
113.86
Volume
1.50M
Turnover
171.09M
Amplitude
4.29%
52-week range
74.50 - 122.20

Valuation

P/E
-36.13
P/E (TTM)
-38.61
P/B
88.54
EPS
-3.11
Net profit
-215.62M
Net assets
87.98M

Share structure

Market cap
7.79B
Float cap
6.35B
Shares out
69.33M
Float shares
56.52M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2017-10-05
52-week range 79% of range
74.50 122.20

8.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+7.62M net over the window

Short interest

Shares short
11.68M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Rhythm Pharmaceuticals (RYTM)?

Rhythm Pharmaceuticals last traded at 112.36. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Rhythm Pharmaceuticals's market cap?

About 7.79B.

What is the P/E ratio of Rhythm Pharmaceuticals?

The trailing twelve-month P/E is -38.61. The Valuation tab shows it against the stock's own five-year range.

Does Rhythm Pharmaceuticals pay a dividend?

Rhythm Pharmaceuticals does not currently pay a regular dividend.

Is Rhythm Pharmaceuticals a buy according to analysts?

The consensus of 15 analysts is a Buy rating, with an average 12-month price target of 149.64, which implies 33.2% upside from the current price. This is not investment advice.

What is Rhythm Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Rhythm Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Rhythm Pharmaceuticals discussion 0 comments

Add a comment